CBR 74 Spółka z Ograniczoną Odpowiedzialnością Spółka Komandytowa (KRS 0000396972, NIP 1181800086) is a Polish company, headquartered in Janów, Mazowieckie voivodeship. CBR 74 Spółka z Ograniczoną Odpowiedzialnością operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since September 23, 2011. CBR 74 Spółka z Ograniczoną Odpowiedzialnością's most recently reported net revenue was 151.6 K PLN for 2024.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - CBR 74
Identity
- Name
- CBR 74 Spółka z Ograniczoną Odpowiedzialnością Spółka Komandytowa
- Legal form
- Limited Partnership (Sp.k.)
- Founded
- September 23, 2011
- Registry status as of
- July 15, 2026
- Latest entry
- July 15, 2026
- Founding act
- 18.07.2011R., NOTARIUSZ MAŁGORZATA TOMCZYK-PERŁOWSKA, KANCELARIA NOTARIALNA W BABICACH NOWYCH UL.WARSZAWSKA 189, REPERTO…
Articles of association history (2)
- July 18, 2011: 18.07.2011R., NOTARIUSZ MAŁGORZATA TOMCZYK-PERŁOWSKA, KANCELARIA NOTARIALNA W BABICACH NOWYCH UL.WARSZAWSKA 189, REPERTORIUM A NR 1699/2011
- November 25, 2014: 25.11.2014 R., NOTARIUSZ MAŁGORZATA TOMCZYK-PERŁOWSKA PROWADZĄCA KANCELARIĘ NOTARIALNĄ W BABICACH NOWYCH (BABICE NOWE UL. WARSZAWSKA 189, 05-082 STARE BABICE) REP. A NR 2170/2014. ZMIENIONO: PAR. 2.1, PAR. 2.2, PAR. 3.
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. WŁADYSŁAWA SIKORSKIEGO, 74, 05-082, JANÓW, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWSKI ZACHODNI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Operational status - CBR 74
Founded
September 23, 2011
14 years in operation
Legal form
Limited Partnership (Sp.k.)
Registry: RejP
Headquarters
JANÓW
MAZOWIECKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Shareholders
2
shareholders
Filed years
6 years
2018–2024 · profitable: 3/6
Registry entries
38
latest: July 15, 2026
Revenue
151.6 K PLN
2024
Net profit
75.5 K PLN
2024
Assets
561.8 K PLN
2024
Equity
560.9 K PLN
2024
EBITDA
127.7 K PLN
2024
Valuation
477.5 K PLN
High confidence
Risk and payment profile - CBR 74
Credibility rating
81 / 100
Very good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/15 yrs
Board changes
0
0/15 yrs
PKD changes
1
1/15 yrs
Name changes
1
1/15 yrs
Data from 15 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: B (81/100)
Trend: improving (+25.4 pts/year)
High payment credibility - the company's financial condition is good and the risk of cooperating with it is low.
Trade credit limit history
Standard limit from 2018–2024
Current: 178.3 K PLN
Safe: 115.9 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Directories and rankings for this location
Related articles
Explainer
Mabion in 2026: Polish monoclonal-antibody maker, mWIG40 issuer from Konstantynów Łódzki, Novavax COVID-19 antigen contract
Mabion S.A. (KRS 0000340462), headquartered at ul. Gen. Mariana Langiewicza 60 in Konstantynów Łódzki, is a Polish biotech specialising in monoclonal-antibody production (key project: MabionCD20, a rituximab biosimilar) and in CDMO (Contract Development and Manufacturing Organization) work. Its main international contract is manufacturing the COVID-19 vaccine antigen for Novavax. Founded in 2007 by Maciej Wieczorek and listed on the WSE since 2010, the company is an mWIG40 constituent, with a three-member management board and a five-member supervisory board.
Explainer
Ryvu Therapeutics in 2026: a Kraków oncology biotech, RVU120 in Phase II clinical trials, a six-member management board, an mWIG40 issuer after the Selvita spin-off
Ryvu Therapeutics S.A. (KRS 0000367359), headquartered at ul. Leona Henryka Sternbacha 2 in Kraków, is a Polish oncology biotech developing anti-cancer small-molecule drugs. It has operated as a stand-alone company since the 2019 spin-off from Selvita (which retained the R&D-services business). Flagship project: RVU120 – a CDK8/19 kinase inhibitor in Phase II trials across multiple oncological indications. Listed on the WSE since 2019 and an mWIG40 constituent, with a six-member management board and a seven-member supervisory board.